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BACKGROUND: The endothelin system is involved in tumour growth. Atrasentan, a selective endothelin-A-receptor antagonist,
blocks endothelin signalling. This phase I trial studied combining treatment of interferon-alpha (IFN-a) with atrasentan in renal cell
carcinoma (RCC).
PATIENTS AND METHODS: This study evaluated the safety and tolerance of IFN-a (9MU subcutaneously (s.c.) three times a week) in
combination with atrasentan (2.5, 5 and 10mg orally once daily) in untreated metastatic RCC. Cohort 10mg was extended to obtain
insights in efficacy and pharmacodynamics.
RESULTS: Observed toxicities mainly consisted of known IFN-like toxicities (anorexia, chills, fever, fatigue and nausea), and of nasal
congestion (associated to atrasentan). None of these toxicities were considered dose limiting. Cohort 10mg was extended up to
32 patients; in a subset of patients treated according to the protocol (n¼ 27), median overall survival (OS) was 17.3 months.
One patient (3.1%) showed a partial response lasting 14.3 months. In an exploratory analysis, we observed that in the subset of
patients with declining vascular endothelial growth factor (VEGF) levels (in combination with rising Endothelin-1 levels), median OS
was 22.2 months compared with 2.2 months in patients with increasing VEGF levels.
CONCLUSION: Combination treatment of IFN-a 9MU-a s.c. three times a week and atrasentan 10mg once daily is tolerated. Clinical
activity, especially OS, and biomarkers in our view warrant further studies targeting the endothelin axis.
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Metastatic renal cell carcinoma (mRCC) has been subject to
many trials with different approaches, including immunotherapy,
chemotherapy and targeted therapy. Until recently and at the
moment of designing this study, interferon-alpha (IFN-a) was
standard care. This cytokine provided survival benefit over
supportive therapy (Coppin, 2008) or hormone therapy with
medroxyprogesterone acetate (Medical Research Council Renal
Cancer Collaborators, 1999). IFN-a-induced toxicity largely con-
sists of flu-like symptoms (Coppin, 2008). Although its anti-cancer
effects are still not comprehensively understood, anti-proliferative,
anti-angiogenic and immunogenic characteristics have been
described (Kirkwood, 2002). The present treatment options,
consisting of sunitinib, sorafenib and bevacizumab, address the
vascular endothelial growth factor (VEGF) pathway (Motzer et al,
2007; Escudier et al, 2007a, b).
The target of the current study is the endothelin axis.
Endothelin-1 (ET-1) is primarily expressed by endothelial cells
but also by cells of certain types of cancer (Nelson et al, 2003).
ET-1 promotes the production of VEGF (Ferrara, 2004), through
enhanced HIF-1a stability and accumulation (Spinella et al, 2002).
Furthermore, ET-1 is mitogenic to cancer cells, and has anti-
apoptotic and tumour-enhancing effects (Spinella et al, 2002;
Nelson et al, 2003; Ferrara, 2004; Bagnato and Rosano, 2008),
mediated by the endothelin-A-receptor (ETAR) (Pflug et al, 2007).
Receptor blockade by specific antagonists inhibits the proliferative
effects of ET-1 in cancer cells (Nelson et al, 2003) and reverses ET-
1-mediated cell survival during chemotherapy-induced apoptosis
(Pflug et al, 2007).
Atrasentan (ABT-627) was developed as a potent, selective
ETAR inhibitor (Opgenorth et al, 1996). Phase I studies reported
maximum tolerated doses of 60mg (Carducci et al, 2002), 75mg
(Ryan et al, 2004) or 95mg (Zonnenberg et al, 2003) once daily.
Most side effects were attributable to the vasoactive nature,
including rhinitis, headache, peripheral oedema and anaemia
(caused by hemodilution). On the basis of pharmacodynamic
characteristics, the dose of 10mg once daily was chosen for further
studies, mostly performed in prostate cancer (Carducci et al, 2003,
2007).
Because ET-1 and ETAR are overexpressed in RCC (Douglas
et al, 2004; Pflug et al, 2007), suggesting pathological endothelin
signalling, and because of complementary mechanisms of action
exercised by atrasentan and IFN-a, we hypothesised that mRCC
patients might benefit from combining these agents. This phase I
study evaluates the safety of combination treatment with
atrasentan 10mg once daily and IFN-a 9MU subcutaneously
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(s.c.) three times a week. An extension cohort was included to
obtain an insight into toxicities in a larger set of patients, and to
obtain an insight in anti-tumour effects and pharmacodynamics in
an exploratory analysis of VEGF and ET-1 kinetics.
PATIENTS AND METHODS
Study design
This open-label phase I study protocol was reviewed and approved
by Institutional Review Boards of the participating centres and
conducted according to institutional, national and European guide-
lines. Patients were required to provide written informed consent
before study participation. This study was not registered in a trial
database, as this was not common practise at the time of initiation.
Patient enrolment was between January 2003 and May 2007.
Dose escalation The primary objective of the dose escalation part,
performed by the University Medical Center Utrecht only, was to
demonstrate the safety and tolerability of combination treatment
of IFN-a (IFN-a-2a, Roferon, Roche; Roche Nederland, Woerden,
The Netherlands) 9MU s.c. three times a week and atrasentan
(Abbott Laboratories, Chicago, IL, USA) 10mg orally once daily. A
fixed dose of IFN-a was combined with escalating doses of
atrasentan (2.5, 5 or 10mg once daily) in three predefined
consecutive cohorts, according to a standard design of 3–6
patients per cohort. Atrasentan was started 2 weeks after the first
administration of IFN-a. Dose escalation was based on at least
three assessable patients per dose level completing 4 weeks of the
combination treatment. Dose limiting toxicity (DLT) was defined
as grade 3/4 adverse events occurring in the first 4 weeks of
combination treatment, except for nausea, vomiting and fever.
Standard supportive care consisted of anti-pyretics (acetamino-
phen) and anti-emetics (metoclopramide).
Extension of cohort 10mg The objective of the extension of
cohort 10mg, performed at two centres, was to obtain better
insight into the toxicity and to obtain information on progression-
free survival (PFS), overall survival (OS) and biomarkers
dynamics. All patients received 10mg atrasentan once daily and
the fixed dose of IFN-a as in the phase 1 dose escalation part.
Toxicity evaluation was performed according to Common
Terminology Criteria for Adverse Events version 3.0 (CTCAE).
Toxicities were clustered into treatment periods. Period 1 included
the 2 weeks of IFN-a monotherapy, period 2 the first 4 weeks of
combination treatment and period 3 the episode of continued
treatment thereafter.
Treatment was continued for 1 year or until unacceptable
toxicity or progressive disease (PD) was reported. PD was assessed
according to Response Evaluation Criteria in Solid Tumours
(RECIST). PFS and OS were recorded from start of IFN-a
treatment until documented PD or death. Clinical outcome was
assessed in the patients treated per protocol (exposed to
combination treatment), as depicted in Figure 1. Toxicity was
evaluated in the intent-to-treat group (receiving at least one dose
of IFN-a).
Patients
Patients with histologically confirmed mRCC (including non-clear
cell) without prior systemic treatment were included. Tumour
progression had to be demonstrated within 6 weeks before the start
of study treatment. Other key eligibility criteria included age 418
years, life expectancy of more than 3 months, WHO performance
status score of 0–2 and measurable disease. Adequate renal,
hepatic, bone marrow and cardiac functions were required, and
any hypertension needed to be controlled. Exclusion criteria were
primary tumours other than RCC, clinical evidence of cerebral
metastases, immune disease, active infection, use of immuno-
suppressive and/or non-steroidal anti-inflammatory drugs, HIV
positivity, pregnancy or lactation. Radiotherapy had to be completed
at least 4 weeks before the administration of study medication.
Assessments
Patient visits were planned pre-treatment, once a week during the
first 6 treatment weeks, bi-weekly for the next 6 weeks, then every
4 weeks until 36 weeks, followed by every 2 months until treatment
termination. Study procedures consisted of physical examination
and laboratory assessments. Tumour measurements were per-
formed every 8 weeks on-treatment, with appropriate imaging
techniques. After treatment discontinuation, survival evaluation
and PD assessment occurred every 3 months for 1 year, thereafter
every 6 months.
Pharmacodynamic analyses
For an exploratory analysis, plasma samples and platelet counts
were obtained pre-treatment, and 2, 4 and 8 weeks after the first
administration of IFN-a. Plasma ET-1 and VEGF concentrations
were quantified in 27 of 44 patients, using commercially available
ELISA kits (R&D Systems, Minneapolis, MN, USA) following
manufacturer’s protocols.
Statistical analysis
Time-to-event analyses were performed using the Kaplan–Meier
methodology.
Paired t-tests were performed to evaluate the changes in
biomarker levels over time. The log rank test was used to correlate
biomarkers with PFS/OS. Platelet counts were correlated to VEGF
levels with the Pearson correlation coefficient.
For these analyses SPSS (version 15.0; SPSS INC., Chigaco, IL,
USA) was used with defined significance level of Po0.05. Reported
P-values are two-sided.
RESULTS
Conduct of the study
A total of 16 patients were included in three dose escalation
cohorts of the phase I study (Figure 1). The total number of
patients of cohort 2.5mg was eight. Because of a DLT (pulmonary
embolism) in one patient this cohort was extended. One patient
Phase I
Extended
cohort 10 mg
n=31
Ineligible
n=1
Ineligible
n=2
Cohort
2.5 mg
n=8
Cohort
5 mg
n=4
Cohort
10 mg
n=3
n=29
Evaluation
toxicity: n=4
Evaluation
toxicity: n=8
Evaluation
toxicity: n=3
Evaluation toxicity:
n=32
Evaluation clinical
outcome:
n=27 (per protocol)
Figure 1 Patient enrolment and conduct of study.
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did not complete 4 weeks of combination treatment because of
hepatic toxicity ascribed to IFN-a; this patient was replaced.
Unintentionally, the first patient of cohort 5mg received 2.5mg
atrasentan instead of 5mg once daily; this patient was included in
cohort 2.5mg.
One patient of cohort 5mg was ineligible for analysis, as the
pathologist’s review diagnosed metastatic colorectal cancer.
Another patient of this cohort discontinued treatment because of
cerebral metastases, which became clinically manifested at an early
stage of treatment; this patient was replaced and still included in
the safety analysis. DLT’s were not observed in this cohort.
The three initial patients in cohort 10mg did not show any DLT.
A total of 31 patients were enroled in the extension of cohort 10mg
(Figure 1). Two patients were deemed ineligible because of
inadequate performance status and of unconfirmed histological
diagnosis; these patients were excluded from the analysis.
Combining these numbers, the total number of patients evaluated
for toxicity was 32.
Of these 32 patients, 5 did not start atrasentan treatment because
of IFN-a toxicity (including 1 allergic reaction), leaving 27 patients
in the per protocol group. Patient enrolment in the study was
discontinued once sunitinib became available in the Netherlands
for first line treatment of mRCC.
Patient characteristics
Gender, age and MSKCC risk scores of the patient groups, as
depicted in Table 1, were consistent with recent published studies
for RCC (Motzer et al, 2007; Escudier et al, 2007b).
Treatment duration
Results per patient concerning treatment duration and disconti-
nuation, PFS and OS are presented in Table 2.
Phase I Median time on study treatment for the eligible patients
in the escalation part of the study was 163 days (range: 23–364),
evaluated from the start of IFN-a administration. Two patients in
cohort 2.5mg discontinued treatment because of toxicity, three
because of PD and three because of completion of 1 year of
treatment. The discontinuation in cohort 5mg was caused by
toxicity in one patient and PD in two patients. One patient
completed 1 year of treatment. One patient in this cohort required
a 33% dose reduction of IFN-a, following treatment interruption
for 1 week, 2 months after start. In cohort 10mg two patients
discontinued as a consequence of PD, while one patient completed
1 year of treatment.
Extended cohort 10mg Median time on study treatment in the
entire group (n¼ 32) and the treated per protocol group (n¼ 27)
was 68 days (range: 1–364) and 102 days (range: 20–364),
respectively. One patient withdrew the informed consent after 1
month of treatment and one patient discontinued treatment
because of irradiation of remaining lesions, which had regressed
on study treatment. For this patient PFS was censored from the
start of radiation treatment. One patient discontinued treatment
Table 1 Baseline demographics and clinical characteristics
Characteristics
Phase 1
(n¼ 15)
Extended
cohort
10mg (n¼ 32)
All patients
(n¼ 44)
Sex, no. (%)
Male 13 (87) 22 (69) 32 (73)
Female 2 (13) 10 (31) 12 (27)
Median age year (range) 61 (37–73) 60 (35–76) 59 (37–76)
WHO ECOG performance status, no. (%)
Zero 9 (60) 18 (56) 24 (54.5)
One 4 (27) 11 (34) 15 (34)
Two 1 (6.5) 1 (3) 2 (4.5)
Unknown 1 (6.5) 2 (6) 3 (7)
Tumour histologic type, no. (%)
Clear cell 9 (60) 27 (84) 34 (77)
Other/not specified 6 (40) 5 (16) 10 (23)
Previous nephrectomy, no. (%) 10 (67) 23 (72) 31 (70)
Progressive disease, no. (%) 15 (100) 32 (100) 44 (100)
MSKCC risk score, no. (%)
Favarouble 6 (40) 11 (34) 16 (36)
Intermediate 8 (53) 18 (56) 25 (57)
Poor 1 (7) 3 (9) 3 (7)
Abbreviations: ECOG¼ Eastern Cooperative Oncology Group; MSKCC¼Memorial
Sloan-Kettering Cancer Center; WHO¼World Health Organization. Percentages
may not be a total of 100 because of rounding.
Table 2 Results per patient concerning treatment duration and
discontinuation, PFS and OS
Cohort Patient
Treatment
duration
(mo)
PFS
(mo)
OS
(mo)
Reason of
discontinuation Alive
Sunitinib/
sorafenib
2.5mg 1 11 15 21.1 1 year treatment
2 7.7 7.7 8.3 PD
3 0.6 0.6 1.8 Toxicity
4 0.8 1.3 5.5 DLT
5 12 27.2 57.1 1 year treatment
6 3.5 3.5 5.4 PD
7 1.8 1.8 20.8 PD
8 12 21.6 58.3 1 year treatment Yes
5.0mg 9 12.1 24 66.7 1 year treatment
10 1 1 2.2 PD
11 11.3 12.3 76.1 Toxicity Yes Yes
12 2 2 9.6 PD
10.0mg 13 12.1 22 68.3 1 year treatment Yes Yes
14 3.4 3.4 22.1 PD
15 5.4 5.4 6.3 PD
10+ 16 5.8 5.8 25.2 PD
17 11.5 7.5 26 PD
18 2.1 2.1 5.2 PD
19 2.2 5.2 30 Toxicity
20 0.4 0.4 2.3 Toxicity
21 0.7 2.8 13.7 Toxicity
22 2.2 2.2 17.1 PD
23 11.2 18.3 34.6 1 year treatment
24 5.8 5.8 12.4 PD
25 6 6 33.7 PD Yes
26 6.1 6.1 11.6 PD
27 0.9 1.3 2 Toxicity
28 9.9 9.9 16 PD Yes
29 0.1 0.1 0.7 Toxicity
30 2.2 2.2 5.4 PD
31 0.7 0.7 2.4 Toxicity
32 0.5 1.4 7 Toxicity Yes
33 5.9 5.9 45.5 Toxicity Yes Yes
34 0.2 0.7 2.2 Toxicity
35 2 2 15.7 Toxicity Yes
36 2.5 6.9 19.9 Toxicity Yes
37 2.3 2.3 17.3 PD
38 3.7 3.7 19.8 PD
39 5.1 5.1 30.2 PD
40 1.8 1.8 12 PD
41 6.2 16.4 48.8 Radiotherapy Yes
42 0 9.9 26.3 Toxicity Yes
43 1.4 1.4 3 PD
44 0.9 5.2 24.1 Withdrew consent
Abbreviations: DLT¼ dose-limiting toxicity; OS¼ overall survival; PD¼ progressive
disease; PFS¼ progression-free survival.
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because of PD, however, retrospectively this patient had PD earlier
during treatment. Other treatment discontinuations were due to
completion of 1 year of treatment (n¼ 2), PD (n¼ 16) and toxicity
(n¼ 12). From the latter 12 patients, 5 received o2 weeks of
treatment (only IFN-a), 3 patients 3–4 weeks, 3 patients
approximately 2.5 months (1 patient received only 2 weeks
atrasentan, but continued with IFN-a) and 1 patient 6 months.
Three patients discontinued IFN-a prematurely after 2, 4 and 5.5
months, but continued atrasentan for an additional 4, 2 and 1
month, respectively. Five patients halted atrasentan treatment after
3 weeks, 1.5 months, 1.5 months, 2 months and 8 months of study
start, but continued IFN-a for an additional 1.5 months, 1 week, 3
weeks, 3 weeks and 2 months, respectively.
Toxicity: phase I plus extension of cohort 10mg
Table 3 shows grade 1/2 treatment-related toxicity when observed
in more than one patient and all grade 3/4 adverse events of both
phase I study, and the extension of cohort 10mg. The three
atrasentan dose levels were combined, as the occurrence of adverse
events was similar both quantitatively and qualitatively (data not
shown). All reported non-laboratory adverse events were grade 2
or less, except for fever (excluded as DLT), allergic reaction and
pulmonary embolism. Notably, the most adverse events began in
period 1 (IFN-a monotherapy). Flu-like symptoms generally
diminished over time. Three patients were hospitalised with fever,
most likely attributed to IFN-a, accompanied by anorexia/
vomiting in two patients. One patient was hospitalised because
of an allergic reaction to IFN-a. Three patients had complaints of
dyspnoea, weight loss, malaise, nasal congestion or fatigue,
resulting in the discontinuation of atrasentan while IFN-a
treatment was sustained. Although vasovagal complaints/dizziness
were reported by several patients, no relation to hypotension could
be established as changes in blood pressure were not observed
(data not shown). One hypertensive patient discontinued anti-
hypertensive treatment after the start of study treatment and
remained normotensive throughout the study. Headaches were
handled adequately with acetaminophen.
The observed laboratory abnormalities were as expected from
IFN-a or atrasentan treatment. Approximately 85% of patients
developed grade 1/2 anaemia during period 2 (first 4 weeks of
combination treatment), recovering thereafter. Neutropenia and
lymphocytopenia, observed during long-term treatment, did not
result in infection.
Clinical outcome measures: per protocol group treated
with 10mg once daily atrasentan
Data cut-off was set at the first of August 2010. In Table 4, median
OS and PFS are presented, including data for the separate risk
groups (the MSKCC index was also used for patients with non-
clear histology RCC) (Motzer et al, 2002). Median and PFS in the
per protocol group were 17.3 and 5.1 months, respectively. Best OS
of 30 months was observed in the best risk subset.
Eight patients treated with 10mg atrasentan received treatment
with sunitinib or sorafenib upon disease progression. If censored
for this treatment, median OS extended to 19.8 months. One
patient (3.1%) showed a partial response lasting 14.3 months.
Biomarkers
An exploratory analysis was performed for biomarkers. VEGF
expression is an established biomarker associated with worse
prognosis in RCC and other tumour types (Djordjevic et al, 2007;
Dirim et al, 2008). We reasoned that VEGF and ET-1 levels might
serve as potential biomarkers in this study. In an exploratory
analysis, 27 of 44 patients were categorised into three groups,
according to baseline VEGF levels and dynamics during treatment
(Table 4). Group 1 (n¼ 16) showed low plasma baseline VEGF
levels, which remained low throughout treatment. Group 2 (n¼ 7)
showed elevated baseline levels, which significantly declined
during treatment. Finally, in group 3 (n¼ 4), initially elevated
levels further increased during treatment.
ET-1 levels significantly increased in group 1 and group 2
(Table 5). However, ET-levels did not change in group 3. Survival
analysis was explored for these three groups (Figure 2 and
Table 4). Best OS and PFS were observed in groups 1 and 2.
As platelets are the main transporters of VEGF in the blood
(Verheul et al, 1997) and thrombocytosis is related to tumour
progression (Symbas et al, 2000; Bensalah et al, 2006), platelet
counts were analysed during treatment. Platelet counts appeared to
be related to plasma VEGF concentrations (Pearson’s correlation
Table 3 Overview of laboratory and non-laboratory adverse events
Period 1
(n¼ 44)
Period 2
(n¼ 39)
Period 3
(n¼ 33)
Patient number CTC gradea 1/2 3/4 1/2 3/4 1/2 3/4
Abdominal discomfort 2/1 3/1 5/3
Allergic reaction 1/
Alopecia 1/ 3/
Anorexia 14/11 9/2 8/1
Arrhythmia 2/
Bleeding /2 /2 2/
Chills 27/11 7/3 6/1
Constipation /2 2/1
Cough 3/3 6/3 5/1
Dehydration 5/ 6/ 3/1
Diarrhoea 6/ 3/ 5/
Dizziness 5/1 1/1 2/2
Dyspnoea 5/4 5/2
Oedema limb 10/ 3/
Fatigue 20/11 9/10 6/5
Fever 12/8 1/ 1/2 2/ 1/
Headache 12/ 2/ 1/
Insomnia 2/1 1/2 2/1
Malaise 6/6 1/5 3/
Mood alteration 4/ 2/ /4
Nasal congestion 4/ 17/2 8/
Nausea 14/2 10/1 5/2
Neuropathy /1 /2
Pulmonary embolus /1
Skin problems 2/ 9/2 10/2
Tumour pain 3/2 3/2 8/3
Vasovagal period 2/1 1/
Voixe changes 7/1
Vomiting 2/ 4/
Weight loss 8/ 3/2 2/1
Increased total bilirubin /3
Increased alkaline phosphatase 3/ 2/ 6/2 1/ 7/
Increased gamma-glutamyltranferase 15/7 1/1 16/7 3/1 10/5 2/
Increased aspartate aminotransferase 13/1 14/3 10/
Increased alanine aminotransferase 9/1 14/2 4/2
Increased creatinine 18/1 16/1 14/2
Anaemia 18/7 21/11 1/ 12/12 2/
Trombocytopenia 5/ 8/ 8/
Leucopenia 8/3 12/9 9/8 2/
Neutropenia /2 2/4 1/ 4/4 1/
Lymphocytopenia 1/12 3/ 5/12 6/ 2/13 7/
Hyponatriema 11/1 1/ 11/1 1/ 8/ 1/
Potassium disregulation 11/1 12/1 1/ 6/1
Calcium disregulation 13/ 19/ 17/2 /2
Hypoalbuminemia 7/4 14/6 11/3
Listed are all laboratory and non-laboratory adverse events (for grade 1/2 only when
observed in more than one patient). All severity was graded according to the
National Cancer Institute. Period 1: the 2 weeks of IFN-a´ monotherapy, period 2: the
first 4 weeks of combination treatment, period 3: the episode thereafter. aCommon
Terminology Criteria for Adverse Events, version 3.0.
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coefficient, r¼ 0.64, P¼ 0.01). It is therefore tempting to speculate
that platelets might influence tumour biology. Further exploration
of this observation is ongoing.
DISCUSSION
This is to our knowledge the first reported study to target the
endothelin axis in RCC. In our view, it shows that combination
treatment with 9MU IFN-a s.c. three times a week and 10mg
atrasentan orally once daily in previously untreated mRCC patients
is well tolerated and seems to show biological and clinical activity.
Observed toxicities (anorexia, chills, fever, fatigue, nausea and
nasal congestion) were manageable with supportive care and in
accordance with previous studies on IFN-a or atrasentan. None of
the toxicities were considered dose limiting. The majority of
adverse events originated in the first 2 weeks of IFN-a treatment,
before the administration of atrasentan. The number of toxicity-
related discontinuations (34% of patients) could be largely
attributed to IFN-a, and is comparable to a recent trial combining
bevacizumab with IFN-a (Escudier et al, 2007b). Toxicity profiles
of IFN-a and atrasentan did not seem to influence each other.
The cohort 10mg was extended in order to study toxicity more
extensively and to obtain a first impression of the clinical activity
of this combination. Observed efficacy results showed a median OS
of 17.3 months in the per protocol group and 30 months in the best
risk group, which is higher than Motzer’s defined clinical outcome
expectations for IFN-amonotherapy in mRCC (Motzer et al, 2002).
We are fully aware that inter-study comparison of clinical outcome
is full of limitations. These results suggest an effect of atrasentan
on top of IFN-a. Further clinical studies are needed to clarify this
effect. Collectively, combination treatment with 9MU IFN-a s.c.
three times a week and 10mg atrasentan orally once daily is
tolerated and our data tentatively indicate the notion that this
combination might induce a more indolent course of disease,
possibly contributed by additive and/or synergistic anti-tumour
effects of both the agents.
VEGF is an important target in RCC treatment. IFN-a treatment
recently showed to inhibit VEGF expression or secretion in several
tumour types in vitro and in vivo (Rosewicz et al, 2004; Wu et al,
2005; Raig et al, 2008; Tochizawa et al, 2008). Moreover, ETAR
blockade reduced the promotion of VEGF production (Rosano
et al, 2003; Gorenflo et al, 2007). We observed that, although the
pre-treatment VEGF levels of patients in group 2 were elevated, the
subsequent drop resulted in a clinical outcome that was similar to
group 1 with low VEGF concentrations and the best OS. Although
exploratory in nature and based on only a small number of
patients, these results are of interest because, to our knowledge, no
association between reduction of increased pre-treatment VEGF
levels and improved clinical outcome has been previously
described. We also observed increased ET-1 levels in group 1
and 2 during treatment. If receptor blocking results in increased
levels of the ligand, as observed in other studies as well (Carducci
et al, 2002; Zonnenberg et al, 2003), this supports a role of
atrasentan in these observed pharmacodynamic effects. Further
studies will need to clarify these putative effects of atrasentan.
As to how to proceed, the results of this study in our view
warrant further exploration of the endothelin axis as a target in
mRCC treatment. For a phase II study, a randomised discontinua-
tion trial design for atrasentan with continuous IFN-a or a
randomised study with IFN-a with and without atrasentan would
be the appropriate study designs. However, as the standard of care
has changed from IFN-a to sunitinib, these options are not
realistic. Also, a randomised study comparing combination
treatment IFN-a and atrasentan with the current standard of care
sunitinib is unlikely to be sufficiently supported in the field.
Alternatively, atrasentan could be combined with other targeted
drugs, particularly VEGF and mTOR inhibitors. This seems
Table 4 Summary of the efficacy measures of median overall survival and
median progression-free survival of the per protocol group (treated
with10mg atrasentan) and of groups categorised according to VEGF level
dynamics
Median PFS mo
(95% CI)a
Median OS mo
(95% CI)b
Extended cohort 3, per protocol (n¼ 27)
Favourable (n¼ 10) 5.1 (2.3–7.9) 17.3 (10.9–23.7)
Intermediate (n¼ 15) 5.2 (4.8–5.5) 30.0 (10.0–49.9)
Poor (n¼ 2) 3.5 (0.5–6.5) 16.0 (8.4–23.6)
2.0 5.4
Groups categorised to VEGF levels
Group 1 (stable) (n¼ 16) 5.3 (4.5–6.1) 19.9 (3.9–35.8)
Group 2 (decreasing) (n¼ 7) 6.1 (0–13.5) 22.1 (0–49.1)
Group 3 (increasing) (n¼ 4) 1.3 (1.0–1.7) 2.2 (0–5.7)
Abbreviations: CI¼ confidence interval; OS¼ overall survival; PFS¼ progression-free
survival; VEGF¼ vascular endothelial growth factor. aP-values PFS: per proto-
col¼ 0.317 (favourable+intermediate vs poor), groups categorised to VEGF level
dynamics¼ 0.002 (group 1+2 vs 3). bP-values OS: per protocol¼ 0.016 (favourableþ
intermediate vs poor), groups categorised to VEGF level dynamics¼ 0.000
(group 1+2 vs 3).
Table 5 Plasma levels (pgml1) of VEGF and ET-1 before (baseline) and
during study treatment (t¼ 4 weeks) of groups categorised to VEGF level
dynamics, presented as median and range of each group
Group 1 (n¼16) Group 2 (n¼ 7) Group 3 (n¼4)
Median VEGF levels (range) (pgml1)
Baseline 36.4 (5.6–71.8) 248.9 (103.7–476.9) 119.9 (41.9–628.5)
t¼ 4 wk 21.8 (7.2–61.7) 45.5 (32.7–152.0) 262.9 (162.9–691.6)
P-value* 40.15 0.016 0.045
Median ET-1 levels (range) (pg/ml)
Baseline 3.2 (0.3–5.0) 3.3 (1.9–4.9) 2.9 (1.8–4.9)
T¼ 4wk 4.9 (2.9–7.5) 6.1 (3.8–7.9) 2.6 (0.3–6.7)
P-value* 0.001 0.006 40.15
Each sample was analysed in duplicate; with a coefficient of variation for the assay of
9.4%. Mean of duplicate was used for further calculations. *P-values: paired T-test
baseline vs T¼ 4 weeks.
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Figure 2 Kaplan–Meier estimates of OS of groups categorised to VEGF
level dynamics (definition of groups is outlined in the text and in Table 4).
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especially feasible, as the mild toxicity profiles for atrasentan as a
single agent and in combination with interferon suggest a tolerable
combination with other targeted drugs. Particularly, the VEGF-
reducing activity and vasoactive nature make it an attractive
candidate for combination treatment with TKIs.
In conclusion, we present a study combining atrasentan with
IFN-a in patients with previously untreated progressive mRCC
showing tolerability and clinical anti-tumour effects. Clinical
activity seems to be related to low VEGF levels (either low levels
throughout treatment or elevated baseline levels that declined
during treatment) and to increasing ET-1 levels. These findings
warrant further exploration of targeting the endothelin axis in
mRCC.
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